Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.54 |
| ▸ | EHMT2 | Q96KQ7 | 5/20 | 0.49 |
| ▸ | EHMT1 | Q9H9B1 | 5/20 | 0.49 |
| ▸ | ENPP1 | P22413 | 6/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22455332 | 0.85 | ENPP1 (0.64) | NCF1EHMT2EHMT1ENPP1PDGFRB | |
| SCHEMBL22441543 | 0.85 | NCF1 (0.53) | NCF1EHMT2EHMT1ENPP1PDGFRB | |
| SCHEMBL25678743 | 0.83 | ALDH1A1 (0.40) | NCF1ENPP1ALDH1A1 | |
| SCHEMBL28694022 | 0.82 | NCF1 (0.52) | NCF1EHMT2EHMT1ENPP1PDGFRB | |
| SCHEMBL29354609 | 0.82 | EHMT2 (0.49) | NCF1EHMT2EHMT1ENPP1PDGFRB | |
| SCHEMBL22455397 | 0.82 | NCF1 (0.49) | NCF1EHMT2EHMT1ENPP1PDGFRB | |
| SCHEMBL29357281 | 0.82 | NCF1 (0.49) | NCF1EHMT2EHMT1ENPP1PDGFRB | |
| SCHEMBL28675609 | 0.81 | NCF1 (0.62) | NCF1EHMT2EHMT1ENPP1PDGFRB | |
| SCHEMBL22441522 | 0.81 | NCF1 (0.65) | NCF1EHMT2EHMT1PDGFRBNPC1 | |
| SCHEMBL22441581 | 0.79 | NCF1 (0.53) | NCF1EHMT2EHMT1ENPP1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| WO-2019046778-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | MAVUPHARMA, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | NCF1 414/4885EHMT2 2846/4885EHMT1 1909/4885 |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | NCF1 414/4885EHMT2 2846/4885EHMT1 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.